Investors of Marinus Pharmaceuticals Encouraged to Act Before Class Action Deadline

NEW YORK, June 19, 2024 — The Rosen Law Firm, a global leader in investor rights representation, is issuing a final reminder to the investors of Marinus Pharmaceuticals, Inc. MRNS regarding the approaching deadline to participate in the ongoing securities class action lawsuit. Investors who have purchased the company's securities within the designated class period are urged to seek legal counsel promptly.

Call to Action for MRNS Investors

Marinus Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Radnor, Pennsylvania, is currently under the legal microscope for potential securities violations. The firm is known for focusing its efforts on the development and commercialization of novel treatments for rare seizure disorders. Investors who have purchased securities and suffered a loss are being invited by the Rosen Law Firm to join the class action suit before the important deadline.

About the Securities Class Action

The lawsuit alleges that Marinus Pharmaceuticals may have issued materially misleading business information to the investing public. The class action seeks to recover damages for investors under federal securities laws. To be eligible for recovery, shareholders who have transacted in Marinus Pharmaceuticals' securities within the class period should contact the Rosen Law Firm to secure legal representation.

Participation in the class action could potentially lead to financial restitution for those who acquired MRNS shares and have been financially impacted by any alleged corporate misdeeds. The Rosen Law Firm emphasizes the significance of the deadline and advises investors to act swiftly to ensure their rights are protected.

Investors, Deadline, Lawsuit